Get the Stockscreener App
20.90
5.82%
1.15
After Hours:
20.73
-0.17
-0.81%
Oculis Holding Ag stock is traded at $20.90, with a volume of 294.72K.
It is up +5.82% in the last 24 hours and down -3.60% over the past month.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
See More
Previous Close:
$19.75
Open:
$21.81
24h Volume:
294.72K
Relative Volume:
2.71
Market Cap:
$1.21B
Revenue:
-
Net Income/Loss:
$-75.28M
P/E Ratio:
-10.47
EPS:
-1.9957
Net Cash Flow:
$-57.45M
1W Performance:
+4.87%
1M Performance:
-3.60%
6M Performance:
+10.00%
1Y Performance:
+18.41%
1-Day Range:
$20.61
$22.14
1-Week Range:
$19.61
$22.14
52-Week Range:
$14.00
$23.08
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
20.90 | 1.14B | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Initiated | JP Morgan | Overweight |
| Aug-27-25 | Initiated | Needham | Buy |
| Dec-05-23 | Initiated | Chardan Capital Markets | Buy |
| Oct-05-23 | Initiated | Stifel | Buy |
| Jun-14-23 | Initiated | BofA Securities | Buy |
| Jun-12-23 | Initiated | H.C. Wainwright | Buy |
| Jun-08-23 | Initiated | Robert W. Baird | Outperform |
| May-10-23 | Initiated | Pareto | Buy |
| Apr-28-23 | Initiated | Wedbush | Outperform |
View All
Oculis Holding Ag Stock (OCS) Latest News
What drives Oculis Holding AG stock priceDouble Top/Bottom Patterns & Free Stay Ahead With Picks - earlytimes.in
Oculis (NASDAQ:OCS) Shares Gap UpShould You Buy? - MarketBeat
Oculis gains on FDA breakthrough therapy status (OCS:NASDAQ) - Seeking Alpha
Oculis stock surges after FDA grants breakthrough therapy designation By Investing.com - Investing.com Nigeria
Oculis stock surges after FDA grants breakthrough therapy designation - Investing.com
Oculis Holding AG Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis - marketscreener.com
Oculis Holding Says FDA Granted Breakthrough Therapy Designation for Privosegtor - marketscreener.com
Oculis Holding AG's Privosegtor Receives Breakthrough Therapy Designation for Optic Neuritis Treatment - Quiver Quantitative
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis - GlobeNewswire
Aug Rallies: Can Oculis Holding AG CR5 stock surprise with quarterly resultsEarnings Beat & Reliable Breakout Forecasts - moha.gov.vn
Company director’s stock units vest at Oculis in new disclosure - Stock Titan
How Oculis Holding Ag (OCS) Affects Rotational Strategy Timing - Stock Traders Daily
Wall Street analysts predict a 106.04% upside in Oculis Holding AG (OCS): Here's what you should know - MSN
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
Short Interest in Oculis Holding AG (NASDAQ:OCS) Increases By 105.6% - MarketBeat
Discipline and Rules-Based Execution in OCS Response - Stock Traders Daily
Assessing Oculis Holding (NasdaqGM:OCS) Valuation After FDA Backing for OCS‑05 and PIONEER Program Progress - simplywall.st
Oculis (NASDAQ:OCS) Shares Down 4.3%Time to Sell? - MarketBeat
Net current asset value per share of Oculis Holding AG – FWB:CR5 - TradingView — Track All Markets
Cash per share of Oculis Holding AG Warrants 2023-06.03.28 on OCULIS HOLDING – NASDAQ:OCSAW - TradingView — Track All Markets
Why analysts upgrade Oculis Holding AG Equity Warrant stock2025 Buyback Activity & Safe Entry Zone Tips - Улправда
Advancing Privosegtor Toward PIONEER Registrational Trials Could Be A Game Changer For Oculis (OCS) - simplywall.st
Is Oculis Holding AG (CR5) stock cheap vs fundamentalsQuarterly Market Summary & Daily Technical Forecast Reports - Улправда
Why Oculis Holding AG Equity Warrant stock attracts global investorsMarket Sentiment Summary & Long-Term Growth Stock Strategies - Улправда
Can Oculis Holding AG stock deliver surprise earnings beatMarket Activity Recap & AI Based Buy/Sell Signal Reports - Улправда
How Oculis Holding AG Equity Warrant stock reacts to inflationary pressuresMarket Rally & Low Risk Growth Stock Ideas - Улправда
Take Profit: How Oculis Holding AG Equity Warrant stock benefits from tech adoptionWeekly Market Outlook & Daily Technical Forecast Reports - Улправда
Oculis (NASDAQ:OCS) Given New $40.00 Price Target at Stifel Nicolaus - Defense World
Oculis (NASDAQ:OCS) Now Covered by JPMorgan Chase & Co. - Defense World
Why Oculis Holding AG stock could benefit from AI revolutionJuly 2025 Technicals & Consistent Profit Trade Alerts - Улправда
Should I hold or sell Oculis Holding AG Equity Warrant stock in 2025July 2025 Trends & Low Drawdown Momentum Trade Ideas - ulpravda.ru
Oculis (NASDAQ:OCS) Shares Gap Up on Analyst Upgrade - Defense World
What sentiment indicators say about Oculis Holding AG stock2025 Volume Leaders & Momentum Based Trading Ideas - Улправда
Oculis stock price target raised to $40 by Stifel on neuro-ophthalmology progress - Investing.com South Africa
Stifel Maintains Oculis Holding (OCS) Buy Recommendation - Nasdaq
Can Oculis Holding AG stock sustain revenue growthDividend Hike & Growth Focused Entry Point Reports - Улправда
Will Oculis Holding AG stock rally after Fed decisionsWeekly Trend Recap & Consistent Income Trade Ideas - Улправда
Oculis (NASDAQ:OCS) Shares Gap Up After Analyst Upgrade - MarketBeat
Oculis (NASDAQ:OCS) Price Target Raised to $40.00 at Stifel Nicolaus - MarketBeat
JP Morgan Initiates Coverage on OCS with Overweight Rating | OCS Stock News - GuruFocus
Oculis (NASDAQ:OCS) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - MarketBeat
Recap Report: Is Oculis Holding AG Equity Warrant stock undervalued vs historical averages2025 Price Targets & Entry and Exit Point Strategies - Улправда
JPMorgan Initiates Coverage on Oculis Holding AG With Overweight Rating, $38 Price Target - marketscreener.com
Will Oculis Holding AG Equity Warrant stock split attract more investors2025 Earnings Surprises & Risk Adjusted Buy and Sell Alerts - Bölüm Sonu Canavarı
Why Oculis Holding AG Equity Warrant stock could rally in 2025Gold Moves & Free Community Supported Trade Ideas - DonanımHaber
Bank Watch: Can Oculis Holding AG stock deliver surprise earnings beat2025 Volume Leaders & Safe Entry Zone Tips - Улправда
Investment Review: Will Oculis Holding AG Equity Warrant stock maintain momentum in 2025 - ulpravda.ru
Movement Recap: Is Oculis Holding AG Equity Warrant stock positioned well for digital economy2025 Biggest Moves & Long-Term Safe Investment Ideas - Улправда
How Oculis Holding AG Equity Warrant stock benefits from tech adoption2025 Fundamental Recap & Smart Investment Allocation Insights - Улправда
Aug Retail: Why Oculis Holding AG Equity Warrant stock attracts global investorsTrade Ideas & Reliable Trade Execution Plans - Улправда
Is Oculis Holding AG Equity Warrant stock positioned well for digital economyAnalyst Downgrade & Real-Time Sentiment Analysis - Улправда
Oculis Holding Ag Stock (OCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):